Strut HealthPartner
Compounded injections$130.79/mo
Back to the full metabolic list
Semaglutide: the shortlist
By Peptide Clarity Guide · October 2026
18 providers that offer semaglutide made the shortlist, at $75 to $349 a month. 32 more offer it but aren't picks yet, and the rule each one misses sits by its name.
Who's on it: providers that are In on the metabolic list and sell semaglutide, compounded or brand. Listed in pick order.
We may earn a commission through qualifying provider links at no extra cost to you. Read our selection criteria and funding disclosure. How we earn
Partners on this list
Partner cards: if you join through one, the provider pays us a fee and your price stays the same. The full list below keeps its pick order.
Made the shortlist
Listed in pick order. See how picks work.
Top pick Microdose semaglutide as a weekly shot or held under the tongue.
Compounded injections$248.76/moVisit Goldspan HealthDaily semaglutide tablets or weekly shots, with prepaid plans that lower the price.
Compounded injections$270.49/moVisit Prime Doctor RXCompounded semaglutide or brand Wegovy access, with a monthly membership on top.
Brand pills$349/moVisit AgelessRxThe product FAQ names network pharmacies; verify the facility assigned to your order.
Compounded injections$89/moVisit altRxStrut HealthPartner
Compounded semaglutide shots with free follow-ups and no membership fee.
Compounded injections$130.79/moVisit Strut HealthCompounded semaglutide at one flat monthly price through every dose step.
Compounded injections$149.99/moVisit Precision TelemedCompounded semaglutide shots or tablets, or brand Ozempic at its own 4-week price.
Compounded injections$227.04/moVisit Luvo HealthGala GLP-1Partner
GLP-1 care with a dose log, refill reminders and a care team seven days a week.
Compounded injectionsPrice on requestVisit Gala GLP-1A consult for brand Wegovy, with the drug billed by its maker.
Brand injectionsPrice on requestVisit PauseRxMonth-to-month or prepaid GLP-1 plans, with the visit and shipping in the price.
Compounded injections$99/moVisit SnagRxGLP-1 clinician review is included; confirm monitoring and the complete recurring quote.
Compounded injections$129/moVisit BrightmedsCompounded semaglutide with overnight shipping, no membership and four plan lengths.
Compounded injections$165/moVisit HealthRXThe GLP-1 service bundles care and educational programs; outcomes remain individual.
Compounded injections$174.72/moVisit TeleZen MDCompare the exact GLP-1 preparation, dose and renewal amount before enrollment.
Compounded injections$299/moVisit WillowCompounded semaglutide, standard or microdose, with every plan length priced.
Compounded injectionsPrice on requestVisit LttlFlat-priced GLP-1s plus doctor messaging and dietitian Q&As on a yearly membership.
Compounded injections$75.58/moVisit CollectiveWeekly GLP-1 shots with every billing term and its full charge printed up front.
Compounded injections$175/moVisit Trimi HealthCoreAge RxPartner
Compare the advertised price-lock policy alongside the written renewal agreement.
Compounded injectionsPrice shown after a few questionsVisit CoreAge Rx
Not a pick yet
Arc-1 Not yet
Why: Prints no cancellation terms for its monthly subscriptions.
When the gap closes, Arc-1 can move to In.
Read the pickBayan Health Not yet
Why: Investigational peptide listings leave the qualifying access pathway unclear.
When the gap closes, Bayan Health can move to In.
Read the pickBelle Not yet
Why: Confirm the dispensing pharmacy, payment schedule and order-stage refund terms.
When the gap closes, Belle can move to In.
Read the pickBioGlow Health Not yet
Why: Approximate month-supply prices do not establish automatic refill charges or dates.
When the gap closes, BioGlow Health can move to In.
Read the pickbmiMD Not yet
Why: Terms describe twenty-eight-to-thirty-day renewal and separate quarterly billing.
When the gap closes, bmiMD can move to In.
Read the pickDefy Medical Not yet
Why: Medication, testing and consultation costs require an itemized personalized quote.
When the gap closes, Defy Medical can move to In.
Read the pickDirectMeds Not yet
Why: Its BPC-157 listing does not meet the reviewed routine commercial compounding conditions.
When the gap closes, DirectMeds can move to In.
Read the pickDudeMeds Not yet
Why: The reviewed disclosures do not identify the pharmacy filling the selected order.
When the gap closes, DudeMeds can move to In.
Read the pickEden Not yet
Why: GLP-1 no-membership claims differ from recurring-membership terms.
When the gap closes, Eden can move to In.
Read the pickEdgeRx Not yet
Why: Names Strive Pharmacy as its one pharmacy, but not which Strive site ships.
When the gap closes, EdgeRx can move to In.
Read the pickElitePhysiqMD Not yet
Why: Its investigational peptide catalog leaves the qualifying access pathway unclear.
When the gap closes, ElitePhysiqMD can move to In.
Read the pickElleS Not yet
Why: The actual dispensing site and selected payment and refund agreement need confirmation.
When the gap closes, ElleS can move to In.
Read the pickEmbody Not yet
Why: Confirm the current renewal amount and charge interval before comparing plans.
When the gap closes, Embody can move to In.
Read the pickEnhance MD Not yet
Why: Its partner lists differ; confirm the actual dispensing pharmacy and site.
When the gap closes, Enhance MD can move to In.
Read the pickFound Not yet
Why: Compounded treatment availability by state is not established by its insurance map.
When the gap closes, Found can move to In.
Read the pickFridays Not yet
Why: TRT medication is extra; GLP-1 promotional totals need a selected renewal quote.
When the gap closes, Fridays can move to In.
Read the pickGoodLife Health Not yet
Why: Medication is billed by the pharmacy, and no monthly drug price is published.
When the gap closes, GoodLife Health can move to In.
Read the pickHumeCare+ Not yet
Why: Introductory homepage pricing does not establish the full prepaid renewal agreement.
When the gap closes, HumeCare+ can move to In.
Read the pickKIN Meds Not yet
Why: Starting hormone offers do not settle the selected form, testing and recurring total.
When the gap closes, KIN Meds can move to In.
Read the pickMangoRx Not yet
Why: The TRT testing offer and laboratory costs leave the full medication renewal unclear.
When the gap closes, MangoRx can move to In.
Read the pickMEDGm Not yet
Why: Early charges and term billing require the selected payment schedule in writing.
When the gap closes, MEDGm can move to In.
Read the pickMEDVi Not yet
Why: Product pages contain unresolved numerical compounded-plan price fields.
When the gap closes, MEDVi can move to In.
Read the pickNext Vial Not yet
Why: Starting offers and differing GLP-1 pages leave selected renewal charges unconfirmed.
When the gap closes, Next Vial can move to In.
Read the pickNova Not yet
Why: Prescribing-decline fees and medication and membership charges need clarification.
When the gap closes, Nova can move to In.
Read the pickRNK Health Not yet
Why: Inclusive-price claims differ from terms allowing separate pharmacy fees.
When the gap closes, RNK Health can move to In.
Read the pickScience & Co Not yet
Why: Annual headlines do not establish the selected ongoing invoice and charge interval.
When the gap closes, Science & Co can move to In.
Read the pickShed Not yet
Why: The selected renewal total and charge interval require a written agreement.
When the gap closes, Shed can move to In.
Read the pickSkinnyRx Not yet
Why: Current introductory GLP-1 offers do not establish the later renewal charge.
When the gap closes, SkinnyRx can move to In.
Read the pickSprout Health Not yet
Why: Four-week product renewal differs from monthly policy and legacy payment instructions.
When the gap closes, Sprout Health can move to In.
Read the pickTyde Wellness Not yet
Why: The exact longevity formulation and qualifying access pathway need confirmation.
When the gap closes, Tyde Wellness can move to In.
Read the pickWellorithm Not yet
Why: Monthly pricing and twenty-eight-day terms describe different renewal schedules.
When the gap closes, Wellorithm can move to In.
Read the pickWePeptideRx Not yet
Why: Dose-selector prices differ from the same product page’s overview.
When the gap closes, WePeptideRx can move to In.
Read the pick
One drug, so every card is a semaglutide card
Almost every program on the metabolic list sells semaglutide, so you'll know most of these names already. The difference is what each card measures. Here the price comes from the seller's semaglutide product only. A program whose cheapest metabolic plan is metformin or tirzepatide shows its semaglutide figure instead, or no figure at all if it doesn't publish one.
The small label on each card tells you two more things: whether that semaglutide is compounded or the maker's brand, and the form, such as a weekly shot, a tablet or a drop under the tongue. The order is worked out from semaglutide alone too, so a program can sit higher or lower than it does on the full list.
Brand semaglutide: three products, one molecule
Novo Nordisk makes all the brand semaglutide in the US. Ozempic, a weekly pen first approved in December 2017, is labeled for type 2 diabetes and for heart and kidney risk in type 2 diabetes. Weight loss isn't one of its approved uses.
Wegovy pens, approved in June 2021, carry the weight label for adults and teens 12 and up. Since then the label has added lowering heart-attack and stroke risk in adults with heart disease and excess weight, and a liver disease called MASH. The Wegovy tablet, approved on December 22, 2025, is the daily semaglutide pill with a weight label. The pen label starts at 0.25 mg a week and tops out at 7.2 mg as Wegovy HD.
When a card says Brand, it's one of those, prescribed by the program and usually billed by Novo Nordisk's own pharmacy or yours. PauseRx and KIN Meds charge for the visit and leave the drug bill to the maker; Science & Co does the same for Wegovy pills. The brand-name GLP-1 list puts every approved option side by side.
Compounded semaglutide after the shortage
Most cards here say Compounded. That means a pharmacy mixed the drug for you, and FDA didn't review it for safety, quality or effect before it shipped. Copies were widely allowed only while semaglutide was in shortage. FDA said the shortage was over on February 21, 2025.
The wind-down came in two steps. State-licensed 503A pharmacies lost their grace period in April 2025, and 503B outsourcing facilities on May 22, 2025. A prescriber-documented significant difference for an identified patient can matter to the essentially-copy restriction. FDA also describes limited enforcement discretion for four or fewer copies in a calendar month. Neither provision supplies blanket permission or removes other applicable conditions. Adding B12 alone does not automatically establish the required difference.
Larger-scale compounding is still unsettled. On April 30, 2026, FDA proposed keeping semaglutide off the list of bulk ingredients 503B facilities may use. Comments closed July 30, 2026, and no final notice has come out. FDA also warns that semaglutide sodium and semaglutide acetate are salt forms with no known lawful basis for compounding, and it had logged 990 adverse-event reports tied to compounded semaglutide by the end of May 2026.
None of the trials behind the brand labels tested a compounded product. The semaglutide explainer keeps the full regulatory timeline.
Shots, tablets and drops on this list
Most programs here sell a weekly injection, and a compounded one usually ships as a vial you draw from, not a prefilled pen. FDA has reports of people hospitalized after measuring the wrong amount, so ask how your dose is marked before the first box arrives.
The needle-free options are where products differ most. MangoRx sells Slim, a compounded tablet with vitamin B6 that dissolves in your mouth. Nova and Goldspan Health sell semaglutide you hold under the tongue. None of these is the Wegovy tablet, and none was studied in the brand trials. If skipping needles is the point, the GLP-1 pills list narrows it further.
What semaglutide costs here
The maker's price is the yardstick. Through NovoCare, Wegovy pens cost $349 a month without insurance, Wegovy HD costs $399, and the tablets run $149 to $299 depending on the dose. New patients pay $199 for each of the first two fills of the two starting doses, through December 31, 2026.
Compounded injections with supported standing quotes run $75.58–$349 a month, with a midpoint near $198. The range excludes unresolved recurring totals. Compare the actual supply, dose, required fees and charge interval rather than treating a low medication headline as a complete plan price.
Read the fine print on the figure. Introductory prices can cover only the first supply, and lower longer-plan offers can require a single large payment. Some public policies do not establish the recurring total for a selected treatment. The linked reviews identify those gaps rather than filling them with a promotional number or an assumed renewal interval.
Prices on the cards are each program's standing monthly rate, with verified fixed-day billing annualized over 365 days and divided by 12. A prepaid plan is a bigger bet on a drug whose compounding rules are still moving.
Before you sign up for a semaglutide plan
Base or salt? Ask whether the product is semaglutide base. If the answer is sodium or acetate, FDA's position is that it has no lawful basis.
Which pharmacy, and what kind? Get its name, and whether it's a 503A pharmacy filling your prescription or a 503B facility. The pick review lists what each program names.
The price at your maintenance dose. Some programs hold one price at every dose; others step up. Ask for the figure at the dose you expect to stay on.
What's in the vial? B12, glycine or B6 changes what you're buying, not whether it's FDA-approved.
What if you stop? In the STEP 1 extension, people regained about two-thirds of what they'd lost within a year off the drug. Weighing a switch? Compare the tirzepatide shortlist, read about keeping muscle on Ozempic, or go back to the full metabolic list.
Questions about this list
- How much is semaglutide a month without insurance?
- Wegovy pens cost $349 a month through Novo Nordisk's self-pay pharmacy, and the tablets $149 to $299. Compounded semaglutide injections run $75.58–$349 a month at the programs that publish a price. Each card here shows that program's own semaglutide figure.
- Can pharmacies still compound semaglutide?
- Only in narrow cases. The shortage ended on February 21, 2025, and the grace periods closed that spring. Patient-specific significant-difference provisions and limited essentially-copy enforcement discretion have conditions; neither is blanket permission. Compounded semaglutide is not FDA-approved.
- Is any semaglutide on this list a pill?
- Yes. Several programs prescribe the Wegovy tablet, the approved daily pill, and others sell compounded tablets or under-the-tongue drops. The label on each card names the form and whether it's brand or compounded.
- Is Ozempic the same drug as Wegovy?
- Same molecule, different labels. Ozempic is approved for type 2 diabetes and its heart and kidney risks. Wegovy indications differ by formulation and population. Its injection and tablet labels are not interchangeable; the injection range includes Wegovy HD.
This is general information, not medical advice. A licensed clinician can tell you what fits you. Health note